Diogo Pinto,  —

Articles by Diogo Pinto

Aria CV Wins Competition for Innovative PAH Medical Device

Aria CV, a company developing medical devices for pulmonary hypertension (PH), won the TCT 2018 Shark Tank Competition, a contest created to highlight the most innovative devices and technologies in the field of cardiovascular medicine. The announcement was made by the nonprofit research and educational organization Cardiovascular…

Levosimendan Aids Kidneys in PH Patients with Heart Disease and Renal Impairment, Phase 3 Data Show

Levosimendan, an investigational therapy for pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF), was found to improve workings of the kidneys in PH-HFpEF patients with kidney impairment in a Phase 3 clinical trial. Findings from the study, “Differential effects of levosimendan and dobutamine on glomerular…

Acceleron Launches PULSAR Phase 2 Trial Testing Potential PAH Therapy Sotatercept

Acceleron Pharma, a biopharmaceutical company focused on rare diseases, has announced the start of the PULSAR Phase 2 clinical trial assessing the safety and effectiveness of sotatercept (ACE-011) in adults with pulmonary arterial hypertension (PAH). Sotatercept works by trapping members of the transforming growth factor-beta (TGF-beta) family, particularly those directly…


A Conversation With Rare Disease Advocates